MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Relay Therapeutics
RLAY
|
+$22M |
| 2 |
Intellia Therapeutics
NTLA
|
+$4.6M |
| 3 |
PRVB
Provention Bio
PRVB
|
+$3.46M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$3.21M |
| 5 |
KDNY
Chinook Therapeutics
KDNY
|
+$2.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
uniQure
QURE
|
+$12.4M |
| 2 |
Harmony Biosciences
HRMY
|
+$7.68M |
| 3 |
G1 Therapeutics
GTHX
|
+$3.53M |
| 4 |
Inhibrx
INBX
|
+$2.19M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$1.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q1 2023 Portfolio in Review
As of Q1 2023, MPM BioImpact held 34 positions worth $385M, down 0.14% from $385M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
MPM BioImpact deployed $13.4M of net new capital in Q1 2023, opening 1 new position and adding to 10 existing holdings. Its largest new stake was Relay Therapeutics: 1,225,634 shares worth $20.2M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was uniQure, an estimated $12.4M trimmed.
- MPM BioImpact's largest Q1 2023 buy was Relay Therapeutics: 1,225,634 shares worth $20.2M.
- MPM BioImpact added most to Intellia Therapeutics in Q1 2023, an estimated $4.6M increase.
- MPM BioImpact's biggest Q1 2023 reduction was uniQure, cutting an estimated $12.4M.
- MPM BioImpact fully exited Harmony Biosciences in Q1 2023, selling an estimated $7.68M.
- MPM BioImpact's ten largest holdings make up 70% of its $385M portfolio in Q1 2023.
- MPM BioImpact opened 1 new position and closed 3 in Q1 2023.
- MPM BioImpact's portfolio value fell 0.14% quarter-over-quarter to $385M.
Based on MPM BioImpact's 13F filing for Q1 2023, filed 12 May 2023.